MedTrace Logo

Dapagliflozin for Long COVID Syndrome

NCT06907251 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-05-01

No results posted yet for this study

Summary

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Conditions

  • COVID - 19
  • Long COVID Syndrome
  • SARS CoV-2

Interventions

DRUG

Dapagliflozin (DAPA)

Dapagliflozin 10mg orally once a day for 12 months

DRUG

Placebo

Participants will receive a matching placebo taken once daily by mouth for 12 months.

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2028-06-30
Completion
2029-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06907251 on ClinicalTrials.gov